Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, post-stroke walking difficulty, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart


Date Filing Description Download
07/01/16 8-K Current report filing
06/27/16 8-K/A Amended Current report filing
06/24/16 4 Statement of Changes in Beneficial Ownership
06/21/16 8-K Current report filing

Stock Quote

ACOR (Common Stock) $ 26.07 +0.57 (+2.22%) Volume: 186,324 MORE July 1, 2016

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *

Enter the code shown above.